Navigation Links
IVCC and Syngenta start project for novel insecticidal active ingredient for malaria control
Date:4/24/2009

IVCC and Syngenta, a leading innovator in insecticidal technology, have launched a project to develop a new insecticidal active ingredient for public health applications, as part of IVCC's strategy to break the impasse in development of mosquito control products. Improved and sustainable control of the insects that transmit disease is dependent upon development of new public health pesticides. However, since agrochemical insecticides are not targeted at mosquitoes, their profiles often do not match those required for public health application. This has led to a drought of new public health products.

This project aims to identify lead candidate compounds for a new active ingredient that is effective against adult mosquitoes, in particular against mosquito strains which have developed resistance to the existing pesticides. The Syngenta chemical collection contains more than 2.5 million distinct chemical substances acquired or synthesised over decades of agrochemical research. Researchers for the company believe that this collection could contain a number of potential candidates.

Syngenta has developed a novel screening process for identification of the optimal candidates from their collection. IVCC has collected together an Expert Scientific Advisory Committee which represents a "Who's Who" of the world of insecticide development and this group will review the data generated by the screening process with Syngenta experts to identify the best candidates that will be taken forward to the next phase.

Dr Tom McLean, Senior Executive Officer, explained the importance of IVCC's intervention: "The unique skills base within the agrochemical industry places them in an ideal position to develop new active ingredients for public health applications but the small market for public health pesticides simply could not support the high research and development costs of such a project.

"The role of the IVCC is to unlock the talent and enthusiasm of companies like Syngenta to enable them to take on huge research efforts for public health by absorbing the front end costs. We are delighted by the commitment that Syngenta has shown to this project."

"Syngenta has increased significantly its activities in the Vector Control area since 2008. We are really excited about this second project with IVCC," said Frdric Baur, Global Head Vector Control at Syngenta.

"It represents a key milestone in our long-term commitment to the fight against malaria and other mosquito transmitted diseases. It is an important part of our pledge to improve the health and quality of life in the rural communities. I am confident this new project will accelerate the development of new vector control products, which benefit communities where the need is greatest."


'/>"/>

Contact: Alan Hughes
a.p.hughes@liv.ac.uk
Liverpool School of Tropical Medicine
Source:Eurekalert

Related biology news :

1. Girls who begin dieting twice as likely to start smoking
2. Shape encoding may start in the retina
3. Freshman class sparks start-up company
4. Starting university may be hazardous to your health: study
5. Stowers Institutes Hawley Lab identifies factors responsible for restart of meiotic cycle
6. Starters orders for unique Ph.D.s in sport
7. NJIT start-up company NeuroTrax named best in show
8. Alzheimers starts earlier for heavy drinkers, smokers
9. No time to lose to start thinking sustainability
10. Trustee makes donation to start new solar energy research center at Rensselaer
11. Urea tanks on diesel trucks -- thats the law in the United States starting in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... ANGELES , Feb. 16, 2017   ... ), a clinical-stage biotechnology company developing first-in-class biological ... announced that it has elected to terminate its ... natriuretic peptide receptor agonists, including Cenderitide. ... strategic move as we prioritize our efforts to ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... Research Inc. has further extended its industry leading Biochemistry Services specifically targeting ... state-of-the-art cGMP techniques and methods for the biochemical and biosimilar characterization ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
Breaking Biology Technology: